错配修复缺陷在结直肠癌个体化管理中的作用
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.
作者信息
Zhang Cong-Min, Lv Jin-Feng, Gong Liang, Yu Lin-Yu, Chen Xiao-Ping, Zhou Hong-Hao, Fan Lan
机构信息
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China.
出版信息
Int J Environ Res Public Health. 2016 Sep 8;13(9):892. doi: 10.3390/ijerph13090892.
Abstract
Colorectal cancer (CRC) represents the third most common type of cancer in developed countries and one of the leading causes of cancer deaths worldwide. Personalized management of CRC has gained increasing attention since there are large inter-individual variations in the prognosis and response to drugs used to treat CRC owing to molecular heterogeneity. Approximately 15% of CRCs are caused by deficient mismatch repair (dMMR) characterized by microsatellite instability (MSI) phenotype. The present review is aimed at highlighting the role of MMR status in informing prognosis and personalized treatment of CRC including adjuvant chemotherapy, targeted therapy, and immune checkpoint inhibitor therapy to guide the individualized therapy of CRC.
摘要
结直肠癌（CRC）是发达国家中第三大常见癌症类型，也是全球癌症死亡的主要原因之一。由于分子异质性，用于治疗CRC的药物的预后和反应存在较大个体差异，因此CRC的个性化管理受到越来越多的关注。大约15%的CRC是由错配修复缺陷（dMMR）引起的，其特征为微卫星不稳定性（MSI）表型。本综述旨在强调错配修复状态在告知CRC预后和个性化治疗中的作用，包括辅助化疗、靶向治疗和免疫检查点抑制剂治疗，以指导CRC的个体化治疗。
相似文献
1
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.错配修复缺陷在结直肠癌个体化管理中的作用
Int J Environ Res Public Health. 2016 Sep 8;13(9):892. doi: 10.3390/ijerph13090892.
2
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.程序性死亡配体-1检测及免疫疗法在微卫星不稳定的结直肠癌中是否有作用？第一部分——结直肠癌：微卫星不稳定、检测及临床意义
Arch Pathol Lab Med. 2018 Jan;142(1):17-25. doi: 10.5858/arpa.2017-0040-RA. Epub 2017 Nov 16.
3
Microsatellite instability testing and its role in the management of colorectal cancer.微卫星不稳定性检测及其在结直肠癌管理中的作用。
Curr Treat Options Oncol. 2015 Jul;16(7):30. doi: 10.1007/s11864-015-0348-2.
4
Diagnosis and management of DNA mismatch repair-deficient colorectal cancer.DNA错配修复缺陷型结直肠癌的诊断与管理
Hematol Oncol Clin North Am. 2015 Feb;29(1):29-41. doi: 10.1016/j.hoc.2014.09.008.
5
The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.错配修复状态在结直肠癌中对辅助化疗治疗决策的影响：一项基于澳大利亚人群的多中心研究。
Oncologist. 2016 May;21(5):618-25. doi: 10.1634/theoncologist.2015-0530. Epub 2016 Mar 23.
6
Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.错配修复缺陷型胃癌患者需要辅助化疗吗？-自噬抑制与错配匹配。
Oncologist. 2020 Jul;25(7):e1021-e1030. doi: 10.1634/theoncologist.2019-0419. Epub 2020 Feb 14.
7
High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine.高微卫星不稳定性（MSI-H）结直肠癌：个性化医疗时代预测生物标志物的简要综述
Fam Cancer. 2016 Jul;15(3):405-12. doi: 10.1007/s10689-016-9884-6.
8
The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing.确定结直肠癌错配修复状态的当前价值：常规检测的理论依据
Crit Rev Oncol Hematol. 2017 Aug;116:38-57. doi: 10.1016/j.critrevonc.2017.05.006. Epub 2017 May 20.
9
Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients.散发性结直肠癌患者中微卫星不稳定性的临床意义及预后相关性
Int J Mol Sci. 2017 Jan 6;18(1):107. doi: 10.3390/ijms18010107.
引用本文的文献
1
The efficacy-associated biomarkers for immune checkpoint inhibitors in gastrointestinal cancer: a literature review.胃肠道癌中免疫检查点抑制剂的疗效相关生物标志物：文献综述
J Gastrointest Oncol. 2024 Feb 29;15(1):514-528. doi: 10.21037/jgo-23-843. Epub 2024 Feb 28.
2
Case report: Pathological and genetic features of pancreatic undifferentiated carcinoma with osteoclast-like giant cells.病例报告：伴有破骨样巨细胞的胰腺未分化癌的病理和遗传学特征。
Pathol Oncol Res. 2023 Mar 3;29:1610983. doi: 10.3389/pore.2023.1610983. eCollection 2023.
3
Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives.重新审视临床批准的铂类衍生物的抗癌毒性。
Int J Mol Sci. 2022 Dec 6;23(23):15410. doi: 10.3390/ijms232315410.
4
Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Kidney Renal Clear Cell Carcinoma.肾透明细胞癌中免疫相关亚型的鉴定及肿瘤微环境浸润特征分析
Front Genet. 2022 Jun 29;13:906113. doi: 10.3389/fgene.2022.906113. eCollection 2022.
5
Systematic analysis of the role of SLC52A2 in multiple human cancers.SLC52A2在多种人类癌症中作用的系统分析。
Cancer Cell Int. 2022 Jan 6;22(1):8. doi: 10.1186/s12935-021-02432-7.
6
High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer.高危特征对错配修复缺陷/微卫星高度不稳定的II期结肠癌具有预后意义。
Front Oncol. 2021 Oct 25;11:755113. doi: 10.3389/fonc.2021.755113. eCollection 2021.
7
RFWD3 Participates in the Occurrence and Development of Colorectal Cancer E2F1 Transcriptional Regulation of BIRC5.RFWD3参与结直肠癌的发生发展及BIRC5的E2F1转录调控。
Front Cell Dev Biol. 2021 Oct 12;9:675356. doi: 10.3389/fcell.2021.675356. eCollection 2021.
8
Intravascular emboli relates to immunosuppressive tumor microenvironment and predicts prognosis in stage III colorectal cancer.血管内栓子与免疫抑制性肿瘤微环境相关，并可预测 III 期结直肠癌的预后。
Aging (Albany NY). 2021 Aug 26;13(16):20609-20628. doi: 10.18632/aging.203451.
9
LDH-A negatively regulates dMMR in colorectal cancer.LDH-A 负向调节结直肠癌中的 dMMR。
Cancer Sci. 2021 Aug;112(8):3050-3063. doi: 10.1111/cas.15020. Epub 2021 Jul 4.
10
Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.错配修复状态与转移性结直肠癌青年患者的生存相关。
J Surg Res. 2021 Oct;266:104-112. doi: 10.1016/j.jss.2021.03.040. Epub 2021 May 11.
本文引用的文献
1
Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency.基于错配修复能力的结直肠癌分子亚型中的免疫组织化学和微卫星不稳定性分析
Int J Clin Exp Med. 2015 Nov 15;8(11):20988-1000. eCollection 2015.
2
High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine.高微卫星不稳定性（MSI-H）结直肠癌：个性化医疗时代预测生物标志物的简要综述
Fam Cancer. 2016 Jul;15(3):405-12. doi: 10.1007/s10689-016-9884-6.
3
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.分子生物标志物在结直肠癌个体化治疗中的应用
Clin Gastroenterol Hepatol. 2016 May;14(5):651-8. doi: 10.1016/j.cgh.2016.02.008. Epub 2016 Feb 9.
4
New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer.基于DNA错配修复和BRAF状态的转移性结直肠癌新治疗机会
Curr Oncol Rep. 2016 Mar;18(3):18. doi: 10.1007/s11912-016-0504-2.
5
Implications of mismatch repair-deficient status on management of early stage colorectal cancer.错配修复缺陷状态对早期结直肠癌治疗的影响。
J Gastrointest Oncol. 2015 Dec;6(6):676-84. doi: 10.3978/j.issn.2078-6891.2015.065.
6
Microsatellite instability in colorectal cancer: clinicopathological significance.结直肠癌中的微卫星不稳定性：临床病理意义
Pol J Pathol. 2015 Sep;66(3):203-18. doi: 10.5114/pjp.2015.54953.
7
Lynch syndrome in the 21st century: clinical perspectives.21世纪的林奇综合征：临床视角
QJM. 2016 Mar;109(3):151-8. doi: 10.1093/qjmed/hcv137. Epub 2015 Jul 29.
8
Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy.错配修复缺陷型癌症是抗 PD-1 治疗的靶点。
Cancer Cell. 2015 Jul 13;28(1):11-3. doi: 10.1016/j.ccell.2015.06.012.
9
Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.错配修复基因与转移性结肠癌中基于伊立替康的化疗之间的关联。
Tumour Biol. 2015 Dec;36(12):9599-609. doi: 10.1007/s13277-015-3723-5. Epub 2015 Jul 5.
10
Microsatellite instability testing and its role in the management of colorectal cancer.微卫星不稳定性检测及其在结直肠癌管理中的作用。
Curr Treat Options Oncol. 2015 Jul;16(7):30. doi: 10.1007/s11864-015-0348-2.
Zotero 插件